1-8 of 8
Andrew Brenner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CC02-01: Regulation of FASN expression through a novel IGF-1R-mTORC1-SRPK2-SRSF1 pathway

Bryan Mcclellan, Paul Gries, Brittany Harlow, Andrew Brenner, Stefano Tiziani, Christopher Jolly, Linda deGraffenried
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): CC02-01.
https://doi.org/10.1158/1535-7163.TARG-21-CC02-01
Published: 01 December 2021
View article titled, Abstract CC02-01: Regulation of FASN expression through a novel IGF-1R-mTORC1-SRPK2-SRSF1 pathway
Journal Articles

Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors

Muhammad Shaalan Beg, Andrew Brenner, Jasgit Sachdev, Samuel Ejadi, Mitesh Borad, Yang-Kon Kang, Ho Lim, T-Y Kim, Andreas Bader, Jay Stoudemire, Susan Smith, Sinil Kim, David Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C43.
https://doi.org/10.1158/1535-7163.TARG-15-C43
Published: 01 December 2015
View article titled, Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors
Journal Articles

Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation

Andrew Brenner, Jeffrey Infante, Manish Patel, Hendrik-Tobias Arkenau, Mark Voskoboynik, Erkut Borazanci, Gerald Falchook, L.R. Molife, Shubham Pant, Emma Dean, Lorraine Pelosof, Suzanne Jones, Chris Rubino, William McCulloch, Valentina Zhukova-Harrill, George Kemble, Marie O'Farrell, Howard A. Burris, III
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A54.
https://doi.org/10.1158/1535-7163.TARG-15-A54
Published: 01 December 2015
View article titled, Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation
Journal Articles

Abstract A70: Clinical outcomes and survival of advanced renal cancer patients in Phase I clinical trials.

Laeeq Malik, Helen Parsons, Devalingam Mahalingam, Benjamin Ehler, Martin Goros, Andrew Brenner, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A70.
https://doi.org/10.1158/1535-7163.TARG-13-A70
Published: 01 November 2013
View article titled, Abstract A70: Clinical outcomes and survival of advanced renal cancer patients in Phase I clinical trials.
Journal Articles

Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas

Gangadhara R. Sareddy, Binoj C. Nair, Vijay K. Gonugunta, Quan-guang Zhang, Andrew Brenner, Darrell W. Brann, Rajeshwar Rao Tekmal, Ratna K. Vadlamudi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (5): 1174–1182.
https://doi.org/10.1158/1535-7163.MCT-11-0960
Published: 08 May 2012
View article titled, Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas
Open the PDF for Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas in another window
Includes: Supplementary data
Journal Articles

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 308–316.
https://doi.org/10.1158/1535-7163.MCT-11-0566
Published: 08 February 2012
View article titled, Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract B49: GRN1005 phase I studies: Final results.

Patrick Y. Wen, Jan Drappatz, Andrew Brenner, Tom Mikkelsen, David Schiff, Steven Rosenfeld, Morris Groves, Yijing Shen, Xiaolin Wang, Mona Shing, Betty Lawrence, Jean-Paul Castaigne, Nash Gabrail, John Sarantopoulos, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B49.
https://doi.org/10.1158/1535-7163.TARG-11-B49
Published: 12 November 2011
View article titled, Abstract B49: GRN1005 phase I studies: Final results.
Journal Articles

Abstract B160: ANG1005: New EPiC compound for the treatment of recurrent malignant glioma

Jan Drappatz, Andrew Brenner, Steven Rosenfeld, Tom Mikkelsen, David Schiff, Patrick Wen, Morris Groves, Kelly Elian, Dimitri Fitsialos, Bruno Fraitag, Betty Lawrence, Jean‐Paul Castaigne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B160.
https://doi.org/10.1158/1535-7163.TARG-09-B160
Published: 10 December 2009
View article titled, Abstract B160: ANG1005: New EPiC compound for the treatment of recurrent malignant glioma